These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 32507818)

  • 21. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
    Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
    Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor.
    Sgherza N; Curci P; Rizzi R; Musto P
    Front Oncol; 2021; 11():716751. PubMed ID: 34660279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.
    Sheikh S; Lebel E; Trudel S
    Future Oncol; 2020 Dec; 16(34):2783-2798. PubMed ID: 32875817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current status and future prospects of immunotherapy for multiple myeloma].
    Imai Y
    Rinsho Ketsueki; 2021; 62(5):407-417. PubMed ID: 34108322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Multiple myeloma: update on pathophysiology and management].
    Hanamura I; Iida S
    Rinsho Ketsueki; 2018; 59(5):529-538. PubMed ID: 29877243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.
    Podar K; Pecherstorfer M
    Expert Opin Pharmacother; 2017 Aug; 18(11):1061-1079. PubMed ID: 28604120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New drugs in early development for treating multiple myeloma: all that glitters is not gold.
    Bertamini L; Bonello F; Boccadoro M; Bringhen S
    Expert Opin Investig Drugs; 2020 Sep; 29(9):989-1004. PubMed ID: 32434394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.
    Baines AC; Ershler R; Kanapuru B; Xu Q; Shen G; Li L; Ma L; Okusanya OO; Simpson NE; Nguyen W; Theoret MR; Pazdur R; Gormley NJ
    Clin Cancer Res; 2022 Nov; 28(21):4629-4633. PubMed ID: 35736811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How I treat triple-class refractory multiple myeloma.
    Costa LJ; Hungria V; Mohty M; Mateos MV
    Br J Haematol; 2022 Jul; 198(2):244-256. PubMed ID: 35373352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma.
    Radocha J; van de Donk NWCJ; Weisel K
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current developments in the combination therapy of relapsed/refractory multiple myeloma.
    Maples KT; Joseph NS; Harvey RD
    Expert Rev Anticancer Ther; 2020 Dec; 20(12):1021-1035. PubMed ID: 32969752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current and prospective antibody-based therapies in multiple myeloma.
    Bryer E; DeStefano C; Kazandjian D
    Semin Oncol; 2022 Feb; 49(1):41-47. PubMed ID: 34996619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Belantamab mafodotin for relapsed or refractory multiple myeloma.
    Gil-Sierra MD; Briceño-Casado MDP
    J Oncol Pharm Pract; 2022 Sep; 28(6):1375-1380. PubMed ID: 35306910
    [No Abstract]   [Full Text] [Related]  

  • 35. [Antibody therapy for multiple myeloma].
    Handa H
    Rinsho Ketsueki; 2021; 62(8):1167-1177. PubMed ID: 34497204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Updates in the management of relapsed/refractory multiple myeloma.
    Hanna KS; Larson S; Nguyen J; Tu S; Boudreau J; Rose S
    J Oncol Pharm Pract; 2021 Sep; 27(6):1477-1490. PubMed ID: 34162244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma.
    McCurdy A; Visram A
    Curr Hematol Malig Rep; 2022 Dec; 17(6):306-318. PubMed ID: 36417082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors.
    Driscoll JJ; Brailey M
    Cancer Metastasis Rev; 2017 Dec; 36(4):585-598. PubMed ID: 29052093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
    Varga C; Laubach JP; Anderson KC; Richardson PG
    Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
    Le Ray E; Jagannath S; Palumbo A
    Expert Rev Hematol; 2016 Jan; 9(1):91-105. PubMed ID: 26558304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.